Related Experiment Video
Updated: Feb 16, 2026

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
Published on: September 20, 2024
Antimicrobial Activity of Ibuprofen against Cystic Fibrosis-Associated Gram-Negative Pathogens
Parth N Shah1, Kimberly R Marshall-Batty2, Justin A Smolen1
1Department of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, College Station, Texas, USA.
Abstract:
Clinical trials have demonstrated the benefits of ibuprofen therapy in cystic fibrosis (CF) patients, an effect that is currently attributed to ibuprofen's anti-inflammatory properties. Yet, a few previous reports demonstrated an antimicrobial activity of ibuprofen as well, although none investigated its direct effects on the pathogens found in the CF lung, which is the focus of this work. Determination of ibuprofen's in vitro antimicrobial activity against Pseudomonas aeruginosa and Burkholderia species strains through measurements of the endpoint number of CFU and growth kinetics showed that ibuprofen reduced the growth rate and bacterial burden of the tested strains in a dose-dependent fashion. In an in vitroPseudomonas biofilm model, a reduction in the rate of biomass accumulation over 8 h of growth with ibuprofen treatment was observed. Next, an acute Pseudomonas pneumonia model was used to test this antimicrobial activity after the oral delivery of ibuprofen. Following intranasal inoculation, ibuprofen-treated mice exhibited lower CFU counts and improved survival compared with the control animals. Preliminary biodistribution studies performed after the delivery of ibuprofen to mice by aerosol demonstrated a rapid accumulation of ibuprofen in serum and minimum retention in lung tissue and bronchoalveolar lavage fluid. Therefore, ibuprofen-encapsulated polymeric nanoparticles (Ibu-NPs) were formulated to improve the pharmacokinetic profile. Ibu-NPs formulated for aerosol delivery inhibited the growth of P. aeruginosa in vitro and may provide a convenient dosing method. These results provide an additional explanation for the previously observed therapeutic effects of ibuprofen in CF patients and further strengthen the argument for its use by these patients.
Insights
Ibuprofen exhibits antimicrobial properties against cystic fibrosis lung pathogens like Pseudomonas aeruginosa. This study demonstrates ibuprofen
Area of Science:
- Microbiology
- Pharmacology
- Pulmonology
Background:
- Ibuprofen is used for cystic fibrosis (CF) but its benefits are attributed to anti-inflammatory effects.
- Previous studies suggest ibuprofen has antimicrobial activity, but its effect on CF lung pathogens was unexamined.
Purpose of the Study:
- To investigate the direct antimicrobial activity of ibuprofen against Pseudomonas aeruginosa and Burkholderia species, key CF lung pathogens.
- To evaluate ibuprofen's efficacy in a murine model of Pseudomonas pneumonia and explore novel delivery methods.
Main Methods:
- In vitro antimicrobial assays measuring colony-forming units (CFU) and growth kinetics against P. aeruginosa and Burkholderia.
- In vitro Pseudomonas biofilm model to assess biomass accumulation.
- Murine model of acute Pseudomonas pneumonia to evaluate in vivo efficacy and survival rates.
- Biodistribution studies and formulation of ibuprofen-encapsulated polymeric nanoparticles (Ibu-NPs) for aerosol delivery.
Main Results:
- Ibuprofen dose-dependently reduced the growth rate and bacterial burden of P. aeruginosa and Burkholderia species in vitro.
- Ibuprofen inhibited Pseudomonas biofilm formation and reduced bacterial load and improved survival in a mouse pneumonia model.
- Aerosolized ibuprofen showed rapid serum but minimal lung retention; Ibu-NPs improved in vitro efficacy and offer potential for convenient dosing.
Conclusions:
- Ibuprofen possesses direct antimicrobial activity against key CF lung pathogens, offering a potential mechanism beyond its anti-inflammatory effects.
- These findings support ibuprofen's therapeutic use in cystic fibrosis patients and suggest aerosolized nanoparticle formulations as a promising delivery strategy.
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...
Gram-negative Bacterial Protein Secretion Systems
Antimicrobial Effectiveness
Negative Regulator Molecules
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...

